Table 1 Patient demographics and baseline HRQL.
| Â | Clinical Trial 1 | Clinical Trial 2 | Clinical Trial 3 |
|---|---|---|---|
N | 316 | 685 | 251 |
Male% | 43% | 38% | 39% |
Caucasian% | 89% | 69% | 91% |
Age, mean (s.d.) | 45.5 (13.0) | 47.9 (14.1) | 45.1 (14.1) |
Omeprazole% | 49% | 50% | 52% |
Heartburn Severity%1 | Â | Â | Â |
None/Minor | 21% | 37% | 17% |
Mild | 53% | 34% | 8% |
Moderate | 20% | 24% | 36% |
Severe | 4% | 5% | 39% |
Missing | 2% | 0% | 0% |
Heartburn-related symtoms2 | 3.1 (0.8) | 3.9 (1.0) | 4.5 (1.8) |
PGWB Total, mean (s.d.) | 76.3 (16.4) | 73.0 (18.2) | 58.0 (21.8) |
MOS Sleep, mean (s.d.) | 67.7 (25.7) | NA | 55.5 (29.2) |